Abstract:Background: Sickle cell disease (SCD) is a prevalent autosomal recessive hemoglobinopathy affecting millions worldwide, particularly individuals of African ancestry. Sickle cell disease is a lifelong condition associated with a negative impact on quality of life and mortality, causing complications such as painful vaso-occlusive episodes, acute chest syndrome, stroke, long-term anemia, and end-organ damage. Currently, there are 4 U.S. Food and Drug Administration (FDA)-approved drugs, including hydroxyurea, l-glutamine, voxelotor, and crizanlizumab, which work to alleviate symptoms and prevent complications associated with SCD, albeit without addressing the underlying cause of SCD. Allogeneic hematopoietic stem cell transplant (HSCT) has shown promise as a curative approach to SCD but is limited by donor availability and associated complications. This paper aims to review the efficacy and safety of exagamglogene autotemcel and lovotibeglogene autotemcel for managing patients with SCD, including their place in therapy, cost, and accessibility in clinical care. Data Sources: The authors searched PubMed and Medline from 2017 to 2024, for primary literature on both exagamglogene autotemcel and lovotibeglogene autotemcel. Results: The authors identified relevant studies and summarized the data on the two gene therapies. Conclusion: Exagamglogene autotemcel and lovotibeglogene autotemcel are two management strategies that address the underlying cause of SCD and provide curative potential for patients with SCD.

Blood Spotlight Review on Gene Therapy for Sickle Cell Disease

How I Treat Sickle Cell Disease with Gene Therapy

A Review of Gene Therapies for Hemoglobinopathies

Treating Sickle Cell Disease: Gene Therapy Approaches

Current and Future Therapeutics for Treating Patients with Sickle Cell Disease

Hematopoietic stem cell collection for sickle cell disease gene therapy

Gene Therapies for Sickle Cell Disease

Gene Therapies for Hemoglobinopathies: Promises and Challenges

Gene therapy and gene editing strategies in inherited blood disorders

Therapeutic Gene Editing for Hemoglobinopathies

Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease

Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders

An update review of new therapies in sickle cell disease: the prospects for drug combinations

Current state of gene therapy in sickle cell disease

Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned

Is Allogeneic Transplantation for Sickle Cell Disease Still Relevant in the Era of Gene Therapy?

Novel gene therapies for sickle cell disease, Duchenne muscular dystrophy, and hemophilia A

Genome Editing Therapy for the Blood: Ex Vivo Success and In Vivo Prospects

Gene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation

Successes and challenges in clinical gene therapy

Advancements in Hematopoietic Stem Cell Gene Therapy: A Journey of Progress for Viral Transduction